We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gilead is looking to eventually sub out Truvada for its newer HIV drug Descovy when it comes to pre-exposure prophylaxis. But in the meantime, it’s socking cash into promoting the older brand for PrEP.